McKesson (NYSE:MCK) Releases FY 2026 Earnings Guidance

McKesson (NYSE:MCK) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share guidance of 38.800-39.200 for the period, compared to the consensus earnings per share estimate of 38.660. The company issued revenue guidance of -.

McKesson Stock Down 3.7%

Shares of McKesson stock traded down $31.54 during trading on Wednesday, hitting $819.58. 1,707,572 shares of the stock traded hands, compared to its average volume of 570,304. The stock has a market cap of $101.16 billion, a price-to-earnings ratio of 25.51, a PEG ratio of 1.40 and a beta of 0.40. McKesson has a 52 week low of $570.51 and a 52 week high of $895.58. The firm’s fifty day moving average is $826.85 and its 200-day moving average is $776.36.

McKesson (NYSE:MCK) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $9.34 EPS for the quarter, topping the consensus estimate of $9.19 by $0.15. McKesson had a net margin of 1.04% and a negative return on equity of 248.14%. The firm had revenue of $106.16 billion for the quarter, compared to the consensus estimate of $105.98 billion. During the same period last year, the firm posted $8.03 earnings per share. The business’s revenue was up 11.4% compared to the same quarter last year. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. On average, analysts forecast that McKesson will post 32.77 earnings per share for the current fiscal year.

McKesson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 1st. Shareholders of record on Monday, March 2nd will be given a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 0.4%. The ex-dividend date is Monday, March 2nd. McKesson’s dividend payout ratio is presently 10.21%.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on MCK shares. Evercore ISI reissued an “outperform” rating and issued a $1,000.00 target price on shares of McKesson in a research note on Thursday, November 6th. Weiss Ratings reiterated a “buy (a-)” rating on shares of McKesson in a research report on Monday, December 29th. Wells Fargo & Company raised their target price on shares of McKesson from $816.00 to $914.00 and gave the stock an “equal weight” rating in a report on Monday, November 10th. TD Cowen reissued a “buy” rating on shares of McKesson in a report on Monday, December 22nd. Finally, Morgan Stanley reiterated an “overweight” rating and set a $966.00 target price on shares of McKesson in a report on Thursday, January 29th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, McKesson has a consensus rating of “Moderate Buy” and a consensus price target of $899.36.

Insiders Place Their Bets

In other news, EVP Thomas L. Rodgers sold 276 shares of McKesson stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $816.18, for a total value of $225,265.68. Following the completion of the transaction, the executive vice president owned 2,268 shares of the company’s stock, valued at $1,851,096.24. The trade was a 10.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Napoleon B. Rutledge, Jr. sold 329 shares of the stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $861.63, for a total transaction of $283,476.27. Following the sale, the chief accounting officer directly owned 328 shares in the company, valued at $282,614.64. This trade represents a 50.08% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.08% of the stock is currently owned by insiders.

Key McKesson News

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Q3 results beat expectations — McKesson reported adjusted EPS above consensus and revenue roughly in line, driven by volume growth across distribution. Read More.
• Positive Sentiment: Raised FY‑2026 profit guidance — management nudged full‑year adjusted EPS to a range of 38.800–39.200, citing strength in oncology and specialty drug distribution. That modest beat versus consensus supports the growth story. Read More.
• Neutral Sentiment: Analyst sentiment remains largely positive — multiple firms maintain buy/overweight ratings and price targets above current levels (median targets near $860+), so market expectations stay elevated. Read More.
• Neutral Sentiment: Revenue outcome mixed vs. Street — total revenue was essentially in line with estimates, limiting the upside surprise. Read More.
• Negative Sentiment: Operating cash flow weakness — the quarter showed a sharp drop in cash from operations versus last year, raising concerns about working‑capital swings and free‑cash‑flow reliability. Read More.
• Negative Sentiment: Balance sheet and returns red flags — investors pointed to a negative reported return on equity and a rise in total liabilities, which can temper valuation multiples despite strong top‑line. Read More.
• Negative Sentiment: Insider selling and strategic exits — recent insider sales and McKesson’s full exit from the European market add near‑term uncertainty and may prompt profit‑taking. Read More. Read More.

Hedge Funds Weigh In On McKesson

A number of hedge funds have recently bought and sold shares of the business. SurgoCap Partners LP grew its stake in shares of McKesson by 68.7% in the third quarter. SurgoCap Partners LP now owns 452,261 shares of the company’s stock worth $349,390,000 after acquiring an additional 184,106 shares during the period. Wellington Management Group LLP lifted its holdings in shares of McKesson by 32.9% during the 3rd quarter. Wellington Management Group LLP now owns 618,984 shares of the company’s stock valued at $478,190,000 after buying an additional 153,182 shares during the period. Canada Pension Plan Investment Board boosted its stake in shares of McKesson by 443.0% in the 2nd quarter. Canada Pension Plan Investment Board now owns 105,613 shares of the company’s stock worth $77,391,000 after buying an additional 86,162 shares during the last quarter. Boston Partners grew its holdings in shares of McKesson by 6.7% in the third quarter. Boston Partners now owns 1,330,953 shares of the company’s stock worth $1,027,569,000 after acquiring an additional 83,357 shares during the period. Finally, Man Group plc increased its position in McKesson by 40.1% during the second quarter. Man Group plc now owns 239,324 shares of the company’s stock valued at $175,372,000 after acquiring an additional 68,454 shares during the last quarter. Hedge funds and other institutional investors own 85.07% of the company’s stock.

McKesson Company Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.